Related Experiment Video
Updated: Dec 17, 2025

Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues
Published on: July 8, 2020
A novel chalcone derivative suppresses melanoma cell growth through targeting Fyn/Stat3 pathway
Ling Tang1,2,3, Jing Long2,3,4, Keke Li2,3,4
1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan China.
Background:
Fyn has been documented to have oncogenic features in multiple tumors, which might be a potential therapeutic target, however, few studies on the function role of Fyn and its specific inhibitors in melanoma.
Methods:
We investigated the impacts of Fyn and its inhibitor Lj-1-60 on melanoma through bioinformatics analysis, western blot, cell viability, cell cycle and apoptosis and xenograft tumor model as well as immunohistochemical staining. Pull-down and in vitro kinase assay were used to demonstrate Lj-1-60 targeting Fyn. Transcriptome sequencing and RT-PCR were adopted to confirm the potential mechanisms of Lj-1-60 in melanoma.
Results:
Our findings showed that Fyn was overexpressed in melanoma cells and knocked down of Fyn suppressed the proliferation of melanoma cells. To identify the potential inhibitors of Fyn, our in-house library including total of 111,277 chemicals was conducted to vitro screening, among those compounds, 83 inhibitors were further detected to explore the effect on melanoma cells growth and discovered a novel chalcone derivative Lj-1-60 that exhibited low cellular toxicity and high anti-tumor efficacy. Lj-1-60 directly was associated with Fyn and inhibited the Fyn kinase activity with Stat3 as substrate. What's more, Lj-1-60 suppressed the proliferation of melanoma in vitro and in vivo through inducing cell cycle arrest and apoptosis. Moreover, the activation of Stat3 had also been abrogated both in Lj-1-60 treated melanoma cells or Fyn knocked down cells.
Conclusion:
Our study revealed a novel Fyn inhibitor that could significantly suppress melanoma growth, which is a promising potential inhibitor for melanoma treatment.
Insights
Fyn kinase is overexpressed in melanoma. A novel inhibitor, Lj-1-60, effectively suppresses melanoma cell growth by targeting Fyn and Stat3, offering a promising therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Fyn kinase exhibits oncogenic properties in various tumors.
- Its role and specific inhibitors in melanoma remain underexplored, highlighting a therapeutic gap.
Purpose of the Study:
- To investigate the function of Fyn in melanoma.
- To identify and characterize novel Fyn inhibitors for melanoma treatment.
Main Methods:
- Bioinformatics analysis, western blot, cell viability, cell cycle, apoptosis assays, and xenograft models were employed.
- In vitro kinase assays and pull-down assays confirmed Lj-1-60's direct targeting of Fyn.
- Transcriptome sequencing and RT-PCR elucidated Lj-1-60's mechanism of action.
Main Results:
- Fyn is overexpressed in melanoma; its knockdown inhibits proliferation.
- A novel chalcone derivative, Lj-1-60, was identified as a potent Fyn inhibitor with low toxicity and high anti-tumor efficacy.
- Lj-1-60 suppressed melanoma growth in vitro and in vivo by inducing cell cycle arrest and apoptosis, abrogating Stat3 activation.
Conclusions:
- Lj-1-60 directly inhibits Fyn kinase activity, impacting Stat3 signaling.
- This novel Fyn inhibitor demonstrates significant potential for melanoma treatment.
More Related Videos
11:02The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression
Published on: August 3, 2011
07:20A Novel Stromal Fibroblast-Modulated 3D Tumor Spheroid Model for Studying Tumor-Stroma Interaction and Drug Discovery
Published on: February 28, 2020
Related Concept Videos
Abnormal Proliferation
PI3K/mTOR/AKT Signaling Pathway
Inhibition of Cdk Activity
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...